Catheter Precision enacts 1-for-19 reverse stock split on NYSE American

Catheter Precision, Inc. (NYSE:VTAK), a medical device company whose stock has declined over 90% in the past year according to InvestingPro data, implemented a 1-for-19 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on Friday. The company filed a certificate of amendment to its restated certificate of incorporation with the Delaware Secretary of State on Wednesday. The common stock began trading on a split-adjusted basis at the opening of trading on the NYSE American on Friday and continues to use the ticker symbol "VTAK." The stock has been assigned a new CUSIP number, 74933X 708.

As a result of the reverse stock split, every 19 shares of issued common stock, including treasury shares, were automatically reclassified and combined into one share. The number of issued and outstanding shares of common stock was reduced from approximately 23,327,516 to about 1,227,764. The company’s authorized capital stock remains unchanged at 10 million shares of preferred stock and 60 million shares of common stock.

No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive a cash payment equal to their proportionate interest in the net proceeds from the sale of aggregated fractional shares, after customary fees and expenses.

Proportionate adjustments have been made to the per-share exercise prices and the number of shares underlying outstanding stock options and warrants, as well as to the number of shares available for future awards under equity incentive plans. The conversion prices and ratios of outstanding preferred stock have also been adjusted accordingly.

The reverse stock split was previously approved by stockholders at the company’s annual meeting on July 25, 2025, authorizing the board to select a split ratio between 1-for-5 and 1-for-19.

This information is based on a press release statement included in Catheter Precision’s Form 8-K filing with the Securities and Exchange Commission.

In other recent news, Catheter Precision, Inc. announced it will implement a 1-for-19 reverse stock split of its common stock, effective August 15, 2025. This decision was approved at the company’s annual meeting, where shareholders authorized the board to choose a reverse split ratio between 1-for-5 and 1-for-19. Additionally, Catheter Precision’s board has approved the issuance of a stock purchase warrant to Ladenburg Thalmann & Co., Inc. as partial compensation for services in a recent financing deal. This warrant allows Ladenburg Thalmann to acquire 257,143 shares at $0.5424 per share, pending stockholder approval at the upcoming annual meeting on July 25, 2025.

In another development, Catheter Precision announced an executive change with the departure of Marie-Claude Jacques, the Chief Commercial Officer. David Jenkins, the Executive Chairman and CEO, will temporarily take over her responsibilities until a successor is appointed. These announcements were made through a filing with the Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.